Xarelto, developed to prevent blood clots, has been linked to internal bleeding. A popular drug prescribed to prevent blood clots and avoid strokes has proven dangerous for some patients, causing a range of serious health issues including internal bleeding. Made by Germany-based Bayer AG, Rivaroxaban, marketed as Xarelto, is an oral anticoagulant developed and distributed by Bayer and Johnson & Johnson’s New Jersey-based unit, Janssen Pharmaceuticals.
It’s approved by the US Food and Drug Administration for use in patients who have had knee or hip replacement surgery to reduce the risk of blood clots, which can obstruct the blood flow to the vital organs; and for general treatment of deep vein thrombosis and pulmonary embolism. But in recent years, this billion-dollar product has been linked to irreversible internal bleeding that can lead to hospitalization and death. Known issues include:
Thus far, at least 65 deaths and thousands of adverse health reactions have been attributed to Xarelto use. Now, victims and their families are filing suit, alleging that the company failed to warn the public of health risks and demanding that it be removed from the market. If you have suffered bleeding or other health issues after being prescribed Xarelto, contact an experienced dangerous drug attorney with Jacksonville’s Harrell and Harrell at 800-251-1111.
"*" indicates required fields
